OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW

Oculis Holding AG

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 4, 2026

$7.32+0.03 (+0.41%)

Close on Oct 19, 2026

Oculis Holding AG income statement

Millions of CHF, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	57	52	29	22	9.57	9.34
Operating Expenses	83	74	82	33	14	13
Operating Income	-82	-73	-81	-32	-13	-12
Interest Expense	0.83	0.64	1.32	6.44	5.12	2.63
Interest & Investment Income	1.77	2.17	1.43	0.13	0.02	0.01
Pretax Income	-99	-86	-89	-39	-19	-15
Income Tax Expense	-0.19	-0.16	0.11	0.06	0.03	0.08
Net Income incl. Noncontrolling Interests	-99	-86	-89	-39	-19	-15
EPS (Basic)(per share)	-1.89	-2.12	-2.97	-11.32	-5.84	-5.77
EPS (Diluted)(per share)	-1.89	-2.12	-2.97	-11.32	-5.84	-5.77
Shares Outstanding (Basic, Weighted)(shares)	52	40	30	2.99	2.78	2.58
Shares Outstanding (Diluted, Weighted)(shares)	52	40	30	2.99	2.78	2.58

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 8.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 220.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.